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Nonobstructive Versus Obstructive Coronary Artery Disease in Acute
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Background-—Differences in prognosis and baseline clinical presentation have been documented among patient with acute
coronary syndrome and coronary artery disease with obstructive (ObCAD) or nonobstructive arteries (NObCAD), but the rates of
events largely varied across single studies. We carried out a meta-analysis to compare the clinical presentation and prognosis of
NObCAD versus ObCAD acute coronary syndrome patients, as well as of the subjects with zero versus mild occlusion.
Methods and Results-—Searches were made in MedLine, EMBASE, Cochrane databases, and proceedings of international
meetings up to June 30, 2015. We compared the risk of events of NObCAD versus ObCAD patients using random-effect meta-
analyses. We also performed meta-analyses to estimate the yearly or monthly outcome rates in each single group. In NObCAD and
ObCAD patients, respectively, the combined yearly rates were as follows: 2.4% versus 10.1% (all-cause mortality); 1.2% versus 6.0%
(myocardial infarction), 4.0% versus 12.8% (all-cause mortality plus myocardial infarction), 1.4% versus 5.9% (cardiac death), and
9.2% versus 16.8% (major cardiovascular events). In the studies directly comparing NObCAD versus ObCAD, all of the above
outcomes were significantly less frequent in NObCAD subjects (with risk ratios ranging from 0.33 to 0.66). No differences in any
outcome rate were observed between mild occlusion (1–49% stenosis) and zero occlusion patients.
Conclusions-—NObCAD in patients with acute coronary syndrome has a significantly lower cardiovascular risk at baseline and a
subsequent lower likelihood of death or main cardiovascular events. However, these subjects are still at high risk for cardiovascular
mortality and morbidity, suggesting potential undertreatment and calling for specific management. ( J Am Heart Assoc. 2016;5:
e004185 doi: 10.1161/JAHA.116.004185)
Key Words: acute coronary syndrome • acute myocardial infarction • angina pectoris • coronary artery disease • epicardial
vessel stenosis • meta-analysis • microcirculation • nonobstructive coronary artery disease • obstructive coronary artery
disease • prognosis
C oronary artery disease (CAD) is the leading cause ofdeath, morbidity, and disability in Western countries.1
Among CAD patients, acute coronary syndrome (ACS)
represents a serious concern because of the major adverse
cardiac events (MACE) during follow-up.2
ACS may develop from the erosion or rupture of obstruc-
tive (due to thrombus formation) or nonobstructive coronary
atherosclerotic plaques.3,4 The latter condition, commonly
defined as nonobstructive CAD (NObCAD), is less common
than obstructive CAD (ObCAD), with a prevalence ranging
from 5% to 25%,5,6 and it has been associated with lower rates
of clinical outcomes in several studies.7–10
A recent systematic review compared the death rates of
patients with myocardial infarction and nonobstructive versus
obstructive coronary arteries.6 However, no meta-analyses
directly compared the rates of other outcomes including
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re-infarction, cardiac death, and MACE in NObCAD versus
ObCAD ACS patients.
We carried out a meta-analysis to compare the likeli-
hood of several clinical outcomes in NObCAD and ObCAD
ACS patients, to estimate the rates of events, and to
investigate other hypotheses including the potential differ-
ences in the prognosis of NObCAD subjects with zero or
mild occlusion (0% versus 1–50% stenosis), and the
differences in baseline presentation between NObCAD and
ObCAD subjects.
Methods
Search, Study Inclusion Criteria, and Quality
Assessment
Study inclusion criteria were as follows: (1) inclusion of
patients with obstructive or nonobstructive coronary lesion
ACS at baseline; (2) prospective or retrospective assessment
of ≥1 of the following outcomes: all-cause mortality, myocar-
dial infarction, all-cause mortality plus myocardial infarction,
cardiac death, and MACE. The search was initially made online
in MedLine, Scopus, EMBASE, and the Cochrane Controlled
Clinical Trial Register (up to June 2015, with no language
restriction). The bibliographies of all relevant articles including
reviews were reviewed. When it was not possible to extract
any safety or efficacy outcome from a potentially eligible
study, attempts to contact the corresponding author were
made. The search string was adjusted for each database while
maintaining a common overall architecture. We used various
combinations of the following terms related to 2 main
domains: “death” OR “all-cause death” OR “all-cause mortal-
ity” OR “mortality” OR “cardiac death” OR “death for
cardiovascular disease” OR “myocardial infarction” OR “re-
infarction” OR “MACE” OR “major adverse cardiovascular
events” OR “coronary heart disease” (title/abstract) AND
“coronary heart disease” OR “heart disease” OR “cardiovas-
cular disease” OR “acute myocardial infarction” OR “angina*”
OR “acute coronary syndrome” OR “unstable angina” OR
“non-ST segment elevation myocardial infarction (NSTE-ACS)”
OR “ST-elevation myocardial infarction (STE-ACS)” OR “coro-
nary angiograms” OR “normal coronary angiograms,” OR
“near-normal coronary angiograms” OR “non-obstructive
coronary atherosclerosis” and “obstructive coronary
atherosclerosis” OR “insignificant coronary artery disease”
OR “significant coronary artery disease” OR “mild coronary
artery disease”.
We excluded the studies that reported data only on
particular subtypes of subjects, eg, ACS due to spontaneous
coronary dissection, takotsubo cardiomyopathy, or myocardi-
tis, as well as studies in which coronary angiography in the
acute phase of ACS was not performed. When both ACS and
stable CAD patients were included in a study, we included the
study only if data on ACS subjects could be extracted
separately.
Because all the retrieved studies were observational or
observational subgroup analyses of randomized trials, we
assessed the aspects of the reported methodological quality
using an adapted version of the Newcastle Ottawa Quality
Assessment Scale, evaluating the comparability across groups
at baseline for confounding factors (and examining whether
analyses were adjusted adequately for confounders), the
appropriateness of outcome assessment, length of follow-up,
and missing data handling and reporting.11
Data Extraction
Using a standardized data extraction form, 2 independent
investigators (C.P. and G.M.C.) extracted and tabulated all
data. These investigations were not blinded to authors or to
institutions. Discrepancies were resolved through revision of
the original articles and group discussions. The extracted
information included the following: editorial information (lead
author, publication year, study size, study design, duration of
follow-up, type and source of financial support, and publica-
tion status), clinical presentation of ACS (ST-elevation acute
myocardial infarction, non-ST-elevation acute myocardial
infarction, and unstable angina), study population information
(number of patients for each study, percentage of male
population, age, percentage of patients presenting with
obstructive and nonobstructive coronary artery disease),
coronary risk factors such as smoking, hypertension, dyslipi-
demia, diabetes mellitus, and findings of coronary
angiograms. If the results were presented for more than
1 time-point, the last available results were extracted.
Outcomes and Data Analysis
NObCAD was defined as no epicardial vessel with a stenosis
≥50% by quantitative coronary angiography. Nonobstructive
lesions were additionally grouped as normal coronary vessels
(0% lumen stenosis in all vessels) and mild coronary stenosis
(1–49% lumen stenosis in at least 1 vessel).
The main outcome was all-cause mortality during follow-up;
secondary outcomes were myocardial infarction, all-cause
mortality plus myocardial infarction, cardiac death and MACE,
as defined by the authors. The definitions of cardiovascular
disease for each included study7–10,12–44 are shown in
Table 1, together with study characteristics. We extracted
both adjusted or propensity score matched estimations and
raw data to build 292 tables, at any time-point. However,
adjusted or propensity score matched estimates were avail-
able from 3 studies only,7,8,32 and we thus performed all
analyses using raw data.
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The primary, prespecified hypothesis of the study was that
clinical outcomes were significantly less frequent in NObCAD
than ObCAD patients. This hypothesis was evaluated through
random-effect head-to-head meta-analyses, which included
only the studies reporting data on both ObCAD and NObCAD
subjects.45 All analyses were stratified by follow-up duration
(1–6 months, ≥12 months). The results were expressed with
risk ratio (RR) and 95% CI, and the statistical heterogeneity
was quantified using the I2 metric.46
In order to provide some estimates of the incidence rates
for each selected outcome, we also performed meta-analyses
of event rates (sometimes defined as “proportion meta-
analysis”) combining the data of NObCAD and ObCAD
patients separately.47 Thus, in such analyses we could also
include the studies reporting data on NObCAD subjects only
(or data on ObCAD patients only), and study crude rates were
divided by the number of months of follow-up to estimate the
monthly and yearly rates for each outcome.
Two secondary hypotheses were also investigated: (1)
among NObCAD subjects, some clinical outcomes may be
less frequent in patients with normal artery CAD (0%
stenosis) versus mildly obstructive CAD (1–50% stenosis);
(2) NObCAD patients, as compared to ObCAD subjects, may
have less cardiovascular risk factors at baseline (including
higher age, male sex, diabetes mellitus, hypertension,
dyslipidemia, current cigarette smoking), and they may less
frequently present with STE-ACS at hospital discharge and be
treated with cardiovascular drugs such as angiotensin-
converting enzyme inhibitors, b-blockers, statins, aspirin, or
P2Y12 inhibitors. As for the primary hypothesis, we used
Figure. Flowchart of the studies. NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive
coronary artery disease.
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random-effect meta-analyses comparing the 2 groups
directly, and we estimated the crude outcome rates (or
baseline proportions) in both groups through meta-analyses
of the event rates. A random-effect generic inverse variance
approach was used to estimate the mean age at baseline
within single groups.
Potential publication bias was assessed using funnel plots
(displaying RRs from individual studies versus their precision
[1/SE]), and formally tested through the Egger regression
asymmetry test.
We used StatsDirect 2.7.8 (StatsDirect Ltd, Altrincham,
UK, 2010) and RevMan 5.3 (The Cochrane Collaboration,
2014), to perform, respectively, the meta-analyses of the
event rates and the meta-analyses comparing directly
NObCAD versus ObCAD patients.
Results
Search Results and Overall Study Characteristics
Of the 984 papers initially retrieved (Figure), we identified 33
studies (including a total of 120 548 participants) that
evaluated the selected cardiovascular outcomes in NObCAD
and/or ObCAD patients.* Of those, 11 studies (24 369
participants) did not compare directly NObCAD versus ObCAD
patients, and thus could be included only in the meta-analyses
estimating the rates of each selected outcome by single
group.† Four other studies (8309 participants) were included
only in the meta-analyses evaluating the baseline proportion
of STE-ACS patients by single group.16,21,24,33
As reported in Table 1, 7 of the 33 included studies were
carried out in the United States, 10 in Europe, 6 studies were
international, and the remaining 10 took place in other
countries. Three studies were re-analyses of randomized
controlled trials,7,14,35 3 studies were randomized controlled
trials,20,24,39 and all the others had an observational design.
Seventeen studies had a sample size >1000; 12 were
published after 2010; 25 had a follow-up ≥12 months. Eight
studies further categorized NObCAD patients in mildly versus
zero obstructive CAD, and could thus be included into a
dedicated meta-analysis. In 15 studies the outcomes were
ascertained through medical visits. The included studies
differed widely in the proportion of NObCAD patients and in
several baseline patient’s characteristics, including the mean
age, the percentage of males, diabetics, hypertensive,
dyslipidemic, smokers, and subjects with STE-ACS, unstable
angina, and non-ST elevation myocardial infarction–ACS
(Table S1).
Also, because of the large time span of the studies
included, and sometimes to their long follow-up, the definition
of ACS has been quite heterogeneous both within and across
the studies. Before the Myocardial Universal Definition of
2007, ACS was defined on the basis of symptoms, ECG
abnormalities, and cardiac enzymes (mainly creatine kinase
MB fraction).48 After 2007, the measurement of cardiac
troponin T or I has been preferred over the measurement of
creatine kinase MB fraction or other biomarkers for ACS
diagnosis. Of the 33 included studies, 12 were published
before 2007, and only 1 of these dosed serum troponin and
gave results differentiating unstable angina from non-ST-
segment elevation myocardial infarction.7 After 2007, only 10
studies‡ considered patients with unstable angina, and none
reported outcomes stratified by type of ACS.
Methodological Quality
The methodological characteristics of the included studies, as
measured by the Newcastle Ottawa Quality Assessment
Scale,11 are summarized in Table S2. Almost all studies
adequately selected the cohort of patients and ascertained
the exposure (selection category items); 22 of the 33 studies
adequately addressed at least 2 of the 3 items referred to
outcome assessment and follow-up (length and missing data).
Among the 22 studies included in head-to-head meta-
analyses, the comparability of NObCAD versus ObCAD
subjects was not addressed in 14 studies, and only 8 studies
reported some form of adjustment for potential confounders.
Differences in the Baseline Characteristics of
NObCAD Versus ObCAD Patients
As compared with ObCAD subjects, NObCAD patients were
significantly younger (6.2 years on average), less likely to be
male (RR=0.77), diabetic (RR=0.57), hypertensive (RR=0.87),
dyslipidemic (RR=0.75), and to be treated with angiotensin-
converting enzyme inhibitors (RR=0.86; 47.0% versus 53.7%
among ObCAD patients), b-blockers (RR=0.83; 70.0% versus
79.4%), statins (RR=0.82; 52.1% versus 64.2%), and P2Y12
inhibitors (RR=0.46; 29.2% versus 63.7%) (all P<0.01; Table 2,
Figures S1 through S11). The rate of aspirin treatment was
not significantly different (RR=0.94; 81.7% versus 86.8%
among ObCAD).
Although a few studies reported baseline levels of troponin
and left ventricular ejection fraction in both groups, the 2
prognostic parameters were significantly better in NObCAD
versus ObCAD subjects (+2.44% and 27.2 ng/mL, respec-
tively; both P<0.05) (Figures S12 and S13).
*References 7–10, 12–15, 17–20, 22, 23, 25–32, 34–44.
†References 8, 9, 12–15, 23, 25, 26, 32, 41. ‡References15,19,20,22,30,31,35,36,40,42.
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Overall, the likelihood of being diagnosed with STE-ACS
(rather than non-ST segment elevation–ACS) at baseline was
drastically lower among NObCAD versus ObCAD patients
(RR=0.20; 95% CI: 0.13–0.29; Table 2, Figure S14).
The estimated rates of the above characteristics at
baseline were computed using meta-analyses by single group
and are reported in Table S3 and Figures S15 through S38.
Overall, the results were in line with the meta-analyses
comparing the 2 groups directly: among NObCAD and ObCAD
patients, respectively, the mean ages were 56.9 and
63.2 years, and the proportions of STE-ACS were 14.7% and
73.8%.
Crude Rates of Cardiovascular Outcomes in
NObCAD and ObCAD Patients
Overall, 33 studies were included in at least 1 meta-analysis
to estimate the rates of cardiovascular outcomes in NObCAD
and ObCAD patients (Table 3). In NObCAD patients, the
combined yearly rates of death, myocardial infarction, death
plus myocardial infarction, cardiac death, and MACE were
2.4%, 1.4%, 4.0%, 1.2%, and 9.2%, respectively (Table 3,
Figures S39 through S43). The same rates in ObCAD patients
were 10.1%, 5.9%, 12.8%, 6.0%, and 16.8% (Table 3, Figures
S44 through S48).
Combining the few studies that separately considered
mildly obstructed CAD patients (1–50% stenosis) and normal
artery CAD patients (0% stenosis), the pooled yearly rates of
death, myocardial infarction, and death plus myocardial
infarction were 1.1%, 1.0%, and 2.0%, respectively, in mildly
obstructive CAD patients, and 1.3%, 0.6%, and 2.2% in normal
artery CAD patients (Table 3, Figures S49 through S54). No
meta-analysis of event rates was made for cardiac death and
MACE because the number of studies with follow-up longer
than 6 months was too limited to allow meaningful analyses.
Clinical Outcomes in Nonobstructive Versus
Obstructive CAD
As reported in Table 4, of the 22 studies (including a total of
96 179 participants) that directly compared at least 1
cardiovascular outcome in NObCAD versus ObCAD patients,
18 evaluated all-cause mortality (n=93 178 participants); 8
cardiac death (n=9939); 14 myocardial infarction (n=77 966);
13 all-cause mortality or myocardial infarction (n=77 858);
and 7 evaluated MACE (n=12 289).
As compared with ObCAD patients, NObCAD subjects
showed a significantly lower risk of all of the above cardiovas-
cular outcomes (Table 4, Figures S55 through S59): the RR of
both all-cause death and MACE was 0.53; the RR of cardiac
Table 2. Meta-Analyses Comparing the Baseline Characteristics of NObCAD Versus ObCAD Patients
Baseline
Characteristics
No. Studies
(Total Sample) n/N Risk Ratio (95% CI) P Value I2, %
Male sex 22 (81 586) 3686/7420 vs 50 870/74 166 0.77 (0.72–0.84) <0.001 88
Diabetes mellitus 22 (81 586) 1247/7420 vs 22 166/74 166 0.57 (0.47–0.78) <0.001 86
Hypertension 22 (81 586) 4099/7420 vs 45 511/74 166 0.87 (0.81–0.93) <0.001 82
Dyslipidemia 22 (81 586) 2680/7420 vs 31 035/74 166 0.75 (0.65–0.87) <0.001 93
Current smoking 22 (81 586) 2422/7420 vs 29 282/74 166 0.94 (0.85–1.03) 0.2 81
STE-ACS 11 (21 856) 365/2229 vs 14 382/19 627 0.20 (0.13–0.29) <0.001 93
ACE-inhibitors use 8 (76 380) 3052/6499 vs 37 554/69 881 0.86 (0.80–0.92) <0.001 78
b-Blockers use 8 (76 380) 4419/6499 vs 55 486/69 881 0.83 (0.75–0.93) 0.001 96
Statins use 8 (76 380) 3389/6499 vs 44 892/69 881 0.82 (0.70–0.95) 0.01 98
Aspirin use 8 (76 380) 5311/6499 vs 60 675/69 881 0.94 (0.88–1.01) 0.08 96
P2Y12 inhibitors use 6 (48 023) 1197/4118 vs 27 951/43 905 0.46 (0.39–0.55) <0.001 85
Baseline
Characteristics
No. Studies
(Total Sample) N/N Mean Difference (95% CI) P Value I2, %
Mean age 21 (81 438) 7346/74 092 6.16 (7.85; 4.47) <0.001 94
Mean LVEF 6 (11 245) 553/10 692 2.44 (0.50; 4.39) 0.01 65
Mean Troponin
level, ng/mL
4 (9822) 295/9527 27.2 (10.5; 43.8) <0.001 97
ACE indicates angiotensin-converting enzyme; LVEF, left ventricular ejection fraction; n, number of nonobstructive coronary artery disease subjects; N, number of obstructive coronary
artery disease participants; NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease; STE-ACS, ST-elevation myocardial infarction.
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death was 0.44; and the RR of both myocardial infarction and
death ormyocardial infarctionwas 0.36 (all P<0.05). The results
were similar when analyses were stratified by the length of
follow-up, with the sole exception of cardiac death, which was
not significant when only studies with follow-up ≥12 months
were included. No study reported a significant higher risk of any
outcome for NObCAD versus ObCAD patients. The funnel plots
displaying the RRs versus the logarithms of their standard
errors appear skewed to the left for studies evaluating all-cause
mortality (Figure S60), but not for studies considering the other
outcomes (Figures S61 through S64). The Egger weighted
regression method to detect publication bias identified a
borderline significant asymmetry for trials considering death
(P=0.05).
Among NObCAD patients, the risks of all-cause mortality,
myocardial infarction, or all-cause mortality plus myocardial
Table 3. Meta-Analyses of the Event Rates by Single Group of CAD Patients
Outcomes
ObCAD
(>50% Stenosis)
NObCAD
(0–50% Stenosis) Zero CAD (0% Stenosis) Mild CAD (1–50% Stenosis)
MACE References 18, 27, 31, 36,
38, 40, 42
References 14, 18, 27, 31,
36, 38, 40, 42
References 14, 31, 40 References 14, 31, 40
No. studies (n/N; total
person-months)
7 (2039/11 322; 152 890) 8 (184/1668; 26 842) — —
Estimated pooled rate (95% CI)
Per month 1.40% (0.61%; 2.50%) 0.77% (0.43%; 1.21%) — —
Per year 16.8% (7.32%; 30.1%) 9.24% (5.16%; 14.5%) — —
All deaths References 7, 9, 10, 15, 17, 19,
22, 27–29, 31, 32, 34–42, 44
References 1, 2, 4–9, 11–18,
20, 22, 24, 26, 27, 32
References 8, 13, 14, 28,
31, 32, 39, 40
References 8, 13, 14, 28,
31, 32, 39, 40
No. studies (n/N; total
person-months)
22 (3996/95 895; 657 036) 26 (1007/21 652; 472 754) 8 (31/1498; 23 824) 8 (49/1714; 28 257)
Estimated pooled rate (95% CI)
Per month 0.84% (0.53%; 1.23%) 0.20% (0.14%; 0.27%) 0.11% (0.05%; 0.19%) 0.09% (0.04%; 0.15%)
Per year 10.1% (6.36%; 14.8%) 2.38% (1.69%; 3.18%) 1.28% (0.59%; 2.24%) 1.05% (0.48%; 1.85%)
Cardiac death References 9, 18, 27, 30, 32,
35, 38, 42–44
References 1, 3, 11, 13, 16,
17, 19, 21, 22, 24, 25, 31
References 8, 13, 32 References 8, 13, 32
No. studies (n/N; total
person-months)
10 (713/10 218; 135 001) 13 (54/1794; 43 937) — —
Estimated pooled rate (95% CI)
Per month 0.50% (0.15%; 1.09%) 0.10% (0.03%; 0.20%) — —
Per year 6.00% (1.79%; 13.1%) 1.22% (0.42%; 2.45%) — —
MI References 7, 9, 10, 15, 17–19,
27, 32, 35–44
References 1–4, 7, 9, 11–14,
16–18, 21, 22, 23, 26, 32
References 13, 14, 32,
39, 40
References 13, 14, 32,
39, 40
No. studies (n/N; total
person-months)
18 (3064/81 886; 497 624) 21 (757/20 451; 458 114) 5 (10/1124; 17 528) 5 (16/1146; 17 260)
Estimated pooled rate (95% CI)
Per month 0.49% (0.19%; 0.95%) 0.11% (0.03%; 0.24%) 0.05% (0.01%; 0.14%) 0.08% (0.02%; 0.21%)
Per year 5.88% (2.28%; 11.4%) 1.38% (0.42%; 2.88%) 0.58% (0.06%; 1.63%) 1.01% (0.19%; 2.47%)
All deaths+MI References 7, 9, 10, 15, 17, 19,
20, 27, 32, 35–42, 44
References 1, 2, 4, 7, 9–14,
16–18, 22, 26, 29, 31
References 14, 32, 39, 40 References 14, 32, 39, 40
No. studies (n/N; total
person-months)
17 (7631/81 893; 494 260) 17 (436/9376; 118 170) 4 (22/944; 13 208) 4 (35/975; 13 156)
Estimated pooled rate (95% CI)
Per month 1.07% (0.55%; 1.76%) 0.33% (0.13%; 0.62%) 0.18% (0.08%; 0.33%) 0.17% (0.02%; 0.49%)
Per year 12.8% (6.59%; 21.1%) 3.96% (1.57%; 7.42%) 2.18% (0.95%; 3.91%) 2.03% (0.19%; 5.83%)
CAD indicates coronary artery disease; MACE, major adverse cardiovascular events; MI, myocardial infarction; n, Number of non-obstructive CAD subjects; N, Number of obstructive CAD
participants; NObCAD, nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease.
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infarction did not differ significantly between the subjects
with mildly obstructed versus normal artery CAD (Table 5,
Figures S65 through S67). However, few events were included
in the above meta-analyses, which lacked statistical power,
and no meaningful quantitative analyses could be performed
to evaluate cardiac death and MACE.
Discussion
This meta-analysis re-analyzed all the data published regard-
ing the clinical presentation and outcomes of NObCAD and
ObCAD patients with ACS, attempting to address several
questions and providing quantitative estimates that are
difficult to obtain when studies are examined separately.
The main findings are the following: (1) when compared to
patients with obstructive CAD, the patients with a diagnosis of
NObCAD showed a lower baseline cardiovascular risk as they
are significantly less likely to be old, male, diabetic, hyper-
tensive, or dyslipidemic; (2) non-ST-segment–ACS was the
main pattern of presentation among patients with NObACS;
(3) as logically follows from the above, NObCAD patients have
one third to one half the likelihood of death or a main
cardiovascular event than ObCAD subjects; (4) NObCAD
subjects, however, are still at high risk for cardiovascular
mortality and morbidity, showing yearly rates of death plus
myocardial infarction or MACE as large as 4% and 9.2%,
respectively. Interestingly, while in the short-term follow-up
(1–6 months), the cardiac mortality rate was significantly
lower in nonobstructive ACS patients, these differences did
not persist through the 1-year follow-up, making the rates of
cardiac death and myocardial infarction comparable between
the 2 groups; (5) among NObCAD subjects, having zero
stenosis rather than a mildly obstructive stenosis (1–49%)
does not seem to be associated with a lower risk of death or
cardiovascular outcomes, but these analyses are underpow-
ered and require validation.
The better baseline CHD risk profile of NObCAD versus
ObCAD subjects was already well known and documented in
numerous studies, which listed several potential explanations
related to the progression of the atherosclerotic plaque and
Table 4. Meta-Analyses Comparing the Risk of Clinical Outcomes of NObCAD Versus ObCAD Patients
OutcomesRefs.
No. Studies
(No. Patients) n/N Risk Ratio 95% CI P Value I2, %
MACE18,27,31,36,38,40,42 7 (12 289) 104/967 vs 2039/11 322 0.53 0.44 to 0.64 <0.001 0
Stratified by follow-up duration*
1 to 6 months7,31,36,38 4 (11 943) 41/584 vs 1574/11 359 0.51 0.38 to 0.69 <0.001 0
≥12 months18,27,38,40,42 5 (6353) 76/681 vs 945/5672 0.54 0.43 to 0.68 <0.001 0
All deaths7,10,17,19,22,27–29,31,34–40,42,44 18 (93 178) 149/8120 vs 3180/85 058 0.53 0.40 to 0.70 <0.001 57
Stratified by follow-up duration*
1 to 6 months7,10,19,22,27,31,34–36,38,39 11 (81 515) 74/6681 vs 2160/74 834 0.45 0.28 to 0.72 <0.001 66
≥12 months17,27–29,31,35,37,38,40,42,44 11 (23 784) 87/2097 vs 1323/21 687 0.63 0.50 to 0.80 <0.001 10
Cardiac death18,27,30,35,38,42–44 8 (9939) 27/1093 vs 523/8846 0.44 0.19 to 0.98 0.05 69
Stratified by follow-up duration*
1 to 6 months27,30,35,38 4 (10 051) 17/845 vs 438/9206 0.33 0.12 to 0.91 0.03 65
≥12 months18,27,35,38,42–44 7 (8337) 16/743 vs 264/7594 0.66 0.38 to 1.15 0.14 12
MI7,10,17–19,27,35–40,42–44 14 (77 966) 97/6917 vs 2552/71 049 0.36 0.23 to 0.57 <0.001 66
Stratified by follow-up duration*
1 to 6 months7,10,19,27,35,36,38,39 8 (76 368) 81/6287 vs 2372/70 081 0.35 0.19 to 0.63 <0.001 73
≥12 months17,18,27,35,38,40,42–44 9 (10 047) 21/1125 vs 446/8922 0.41 0.18 to 0.94 0.04 67
All deaths+MI7,10,17,19,20,27,35–40,42,44 13 (77 858) 178/6802 vs 6520/71 056 0.36 0.25 to 0.53 <0.001 79
Stratified by follow-up duration*
1 to 6 months7,10,19,27,35,36,38,39 8 (76 368) 143/6287 vs 6066/70 081 0.34 0.20 to 0.56 <0.001 85
≥12 months17,20,27,35,38,40,42,44 8 (9939) 51/1010 vs 913/8929 0.48 0.35 to 0.67 <0.001 22
MACE indicates major adverse cardiovascular events; MI, myocardial infarction; n, Number of non-obstructive CAD subjects; N, Number of obstructive CAD participants; NObCAD,
nonobstructive coronary artery disease; ObCAD, obstructive coronary artery disease; Refs., references.
*Some studies reported (diverse) data at different time-points,27,31,35,38 and were included in both 1 to 6 and 12+ months meta-analyses; thus the sum of the samples of the stratified
meta-analyses can be larger than the sample of the overall meta-analysis.
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hypothesized a stronger role of nonclassical risk factors
(inflammation, insulin resistance, psychosocial factors, phys-
ical inactivity) in ACS etiology for NObCAD sub-
jects.6,10,28,39,49,50 This meta-analysis adds quantitative
estimates with tight confidence intervals on the distribution
of the most common CHD risk factors in ObCAD and NObCAD
groups, which can be used either for clinical practice or to
support prognostic multivariate modeling.
In all but 627,35,36,38,42,44 of the 60 direct comparisons,
NObCAD patients showed a better prognosis than ObCAD
subjects, with all meta-analyses reporting significantly lower
rates of events, from half to one third of those reported by
ObCAD patients. Also, 5 of the 6 comparisons with divergent
results were underpowered, including 5 or fewer events in the
NObCAD group.27,36,38,42,44 In addition, a lower mortality rate
for patients with myocardial infarction and nonobstructive
coronary arteries was also documented in a recent systematic
review.6 The most likely potential explanations for these
findings include the younger age and the lower rate of
diabetes mellitus (both of which are independent predictor of
MACE) among NObCAD subjects. Also, given the drastically
lower likelihood of baseline presentation with ST-segment-
elevation–ACS of NObCAD patients, it has been suggested
that their average amount of myocardial infarction might be
smaller than that of ObCAD subjects.42
It has been suggested that, among NObCAD patients, those
with normal coronary arteries may carry a lower CHD risk than
the subjects with mildly obstructed CAD, representing a
different population of younger patients with a possible
tendency for spontaneous thrombosis and other etiologies
leading to CAD (eg, takotsubo cardiomyopathy, variant angina
pectoris, microvascular dysfunction, and coronary vasos-
pasm).5,6,31 Indeed, a meta-analysis of 18 studies including
unselected or stable patients without significant epicardial
coronary artery disease reported that coronary events were
6-fold more frequent in patients with mild (0–20%) stenosis and
15-fold more frequent in patients with moderate stenosis (20–
40%), when compared with patients with smooth and normal
arteriograms.48 From the present meta-analysis, a different
picture emerges for ACS. In the noncritical stenosis range,
normal (0%) coronary arteries were associated with no better
prognosis than a nonobstructive (1–49%) coronary stenosis.
Such a discrepancy, however, may be artificial, because (1) our
meta-analyses restricted to NObCAD subjects included a very
scarce number of events and were largely underpowered; (2)
heterogeneous conditions were included under the umbrella
term of NObACS, which may encompass disparate entities,
such as epicardial artery coronary vasospasm, takotsubo acute
cardiomyopathy, cocaine or other illicit drug abuse, sponta-
neous coronary dissection, or even acutemyocarditis with ACS-
like presentation. In fact, a major concern in the clinical
definition of nonobstructive ACS is that the majority of the
included studies did not carry out special diagnostic investiga-
tions to rule out the potential role of microcirculation as a cause
of myocardial acute injury (as shown in Table S4), nor were
diagnostic tests carried out to assess the effective vessel
atherosclerotic burden that is often undetectable at angiogra-
phy due to negative atherosclerotic remodeling.49
Although the prognostic profile of NObCAD patients was
more favorable than ObCAD subjects, the former showed
absolute yearly rates of events as high as 9.2% (MACE) and
4.0% (all deaths plus myocardial infarction), in clear contrast
with the common assumption of a good prognosis for
NObCADs.40 Given that the underlying mechanisms that lead
to clinical presentation of ACS in NObCAD subjects are not
well understood,5,10,39 and that the appropriate therapeutic
approach for such patients is also unknown,31 it has been
suggested that their unfavorable outcome might be explained,
at least in part, by the lower rate of the prescription of
b-blockers, angiotensin-converting enzyme inhibitors, statins,
and antiplatelet drugs.10,40 In our meta-analysis, all of the
above drugs were less frequently prescribed to NObCAD
patients. Unfortunately, none of the included studies reported
data on dual antiplatelet therapy, which is one of the most
important disease-modifying medications, when left ventricu-
lar function is preserved. However, while the vast majority of
patients in both groups received aspirin (81.7% and 86.8% in
NObCAD and ObCAD groups, respectively), P2Y12 inhibitors
were administered only to 29.2% and NObCAD patients (and
63.7% ObCAD subjects), and it could thus be hypothesized
that only a minority of patients with NObCAD were under dual
antiplatelet therapy. This might be due to the fact that the
Table 5. Meta-Analyses Comparing the Risk of Clinical Outcomes of Mildly Obstructive Versus Normal Artery CAD Patients
OutcomesRefs.
No. Studies
(No. Patients) n/N Risk Ratio 95% CI P Value I2, %
All deaths8,14,28,31,39,40 6 (2861) 25/1210 vs 41/1447 0.96 0.46 to 1.97 0.9 31
MI14,39,40 3 (1715) 7/836 vs 12/879 0.63 0.25 to 1.58 0.3 0
All deaths+MI14,39,40 3 (1715) 18/836 vs 27/879 0.72 0.37 to 1.39 0.3 17
CAD indicates coronary artery disease; MI, myocardial infarction; n, Number of non-obstructive CAD subjects; N, Number of obstructive CAD participants; Refs., references.
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decision to treat patients was driven by angiographic results
rather than by clinical presentation, supporting the hypothesis
that these patients are often undertreated, probably in the
belief that NObCAD represents a benign condition.40 Overall,
our findings reinforce the calls for a specific management or
an expansion of formal guidelines to include specific recom-
mendations for secondary prevention measures in NObCAD
patients.5,31
Limitations
Several limitations should be considered in the interpretation of
our data. First, the heterogeneity across studieswas substantial
in both the baseline characteristics and the length of follow-up.
While quantifying the differences in baseline characteristics
was one of the aims of the analysis, we computed yearly and
monthly rates rather than the overall rates of event to reduce
the potential bias deriving from varying follow-ups. In any case,
it cannot be excluded that the higher event rate that typically
occurs in the first 6 months of follow-up might have led to an
overestimate of the event rates in those comparisons where the
number of short-term follow-up studies was larger. Second,
meta-regression might have been used to explore both the
causes of heterogeneity and the independent contribution of
each of the CAD risk factors in determining the excess risk in
ObCAD versus NObCAD subjects. However, any meta-regres-
sion model that we fit was at serious risk of bias due to the
relatively scarce number of individual studies in each meta-
analysis and, most importantly, due to the serious imbalance in
each study sample size between NObCAD and ObCAD subjects
(with 1 NObCAD each 6–20 ObCAD subjects for many studies).
This implies that the overall value of a determined risk factor
(eg, age) of an unbalanced study (eg, Dokainish et al7) is very
similar to the mean age value of the ObCAD group, and studies
with balanced groups seem to have a lower mean age than
thosewith unbalanced groups, regardless of their relative risk of
event. Even exploring other alternative options (eg, age
differential between each study group), the bias caused by
the scarce number of balanced-group studies determined a
serious lack of reliability for any meta-regression, the results of
which were thus not shown. Third, as for all meta-analyses
based upon published studies, although we made an extensive
systematic search, we cannot exclude that additional data exist
that were not considered. Fourth, as previously noted, some of
the meta-analyses were populated by a low number of events
and certainly require confirmation from additional data.
Conclusions
This meta-analysis confirms that ACS patients with and
without obstructive CAD are significantly different. NObCAD
patients have a significantly lower cardiovascular risk at
baseline and a subsequent lower rate of death or a main
cardiovascular event. However, these subjects are still at high
risk for cardiovascular mortality and morbidity, suggesting
potential undertreatment and calling for a specific manage-
ment. Our findings, other than demonstrating a significant
medical treatment gap, highlight an important opportunity for
improving the quality of care and, in turn, the outcomes of
patients being diagnosed with NObACS.50 In the context of
NObCAD, no differences in prognosis were noted between
zero stenosis versus mildly obstructive stenosis (1–49%), but
such analyses require validation.
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